clinical trial · NCT06467357
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
AstraZeneca·phase3·recruiting·n = 620
Biliary Tract CancerGemcitabineCisplatinDurvalumabTrastuzumab deruxtecanRilvegostomig
brief summary
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
started
Aug 12, 2024
primary completion
Jun 12, 2028
completion
May 16, 2029
last updated
Apr 16, 2026
official title
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol